A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects With Pulmonary Arterial Hypertension
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Selonsertib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms ARROW
- Sponsors Gilead Sciences
- 07 Jan 2017 This trial was discontinued in Germany, according to European Clinical Trials Database.
- 21 Dec 2016 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 This trial has been completed in Netherlands.